未知生产厂商
Lintitript is a new, highly specific and potent CCK-A receptor antagonist.
Lintitript is a new, highly specific and potent CCK-A receptor antagonist.
Cholecystokinin (CCK) modulates feeding and dopamine-induced behavior in the central and peripheral nervous system. Lintitript antagonizes the effect of cholecystokinin by binding to the cholecystokinin type A (CCK-A) receptor. This action presumably alters feeding habits, however the exact mechanism of action is not known.
For the treatment of pancreatic cancer and appetite disorders.
